MOLCURE
Molcure is antibody and Peptide drug-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of patients by developing and providing more effective therapeutics and supportive care products. Molcure represents high quality antibody and target discovery. With cutting edge technology in-house, Molcure is the partner of choice for therapeutic antibody discovery. At Molcure they combine a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. The antibody discovery platform Abtracer delivers superior functional antibodies. Their technology is validated through a number of partnerships. They are seeking new partnership opportunities.
MOLCURE
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2013-01-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.molcure.com
Total Employee:
11+
Status:
Active
Contact:
81 235 26 8107
Email Addresses:
[email protected]
Total Funding:
12.03 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Font Awesome Domain Not Resolving Apache Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Investors List
Japan Post Capital
Japan Post Capital investment in Series C - Molcure
STRIVE
STRIVE investment in Series C - Molcure
SBI Investment
SBI Investment investment in Series C - Molcure
JAFCO Group
JAFCO Group investment in Series C - Molcure
GMO VenturePartners
GMO VenturePartners investment in Series C - Molcure
Nippon Chemiphar
Nippon Chemiphar investment in Series C - Molcure
Dai-ichi Life
Dai-ichi Life investment in Series B - Molcure
Nippon Chemiphar
Nippon Chemiphar investment in Series B - Molcure
GMO VenturePartners
GMO VenturePartners investment in Series B - Molcure
UTEC - The University of Tokyo Edge Capital Partners
UTEC - The University of Tokyo Edge Capital Partners investment in Series A - Molcure
Official Site Inspections
http://www.molcure.com Semrush global rank: 6.61 M Semrush visits lastest month: 932
- Host name: ec2-54-65-96-21.ap-northeast-1.compute.amazonaws.com
- IP address: 54.65.96.21
- Location: Tokyo Japan
- Latitude: 35.6882
- Longitude: 139.7532
- Timezone: Asia/Tokyo
- Postal: 102-0082
More informations about "Molcure"
Molcure Inc. | Accelerating drug discovery
Molcure Inc. is an AI company focusing on accelerating drug discovery through the combination machine learning, biotechnology, and robotics.See details»
MOLCURE Inc. - LinkedIn
We are an AI company focusing on accelerating drug discovery & design. MOLCURE was founded in 2013 with a mission to build the best platform for biologics discovery in the world.See details»
Molcure - Crunchbase Company Profile & Funding
Molcure is a high-speed, high-quality, high-variation antibody screening & design system combining biology, automation and bioinformatics. View contacts for Molcure to access new leads and connect with decision-makers.See details»
Molecure
Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need. We aim to become globally recognized for developing breakthrough therapies to treat incurable diseases.See details»
Molcure - VentureRadar
MOLCURE is a growing startup company with a unique biopharmaceutical molecular design technology that makes full use of Artificial Intelligence (AI). Collaborating with pharmaceutical …See details»
Molcure Company Profile 2024: Valuation, Funding
Developer of a bio-pharmaceutical technology intended to assist in drug discovery. The company's services offer users knowledge of next-generation sequencing, bioinformatics, and antibody biology with an automated discovery …See details»
MOLCURE Inc.: Contact Details and Business Profile
MOLCURE Inc. is a Biotechnology Research, Business Services General, and Biopharma company_reader located in Tokyo, Tokyo with $1 million in revenue and 36 employees. Find …See details»
Revolutionizing the world of "drug discovery" A bio-venture
Sep 23, 2021 · MOLCURE is a startup that creates new drugs by providing pharmaceutical companies with "peptide / antibody molecule design technology that integrates artificial …See details»
$7.2 million in Series C Funding AI-driven Drug Discover y
Collaborating with pharmaceutical companies, MOLCURE accelerates drug discovery by developing novel drug candidate molecules. MOLCURE’s patented and validated AI platform …See details»
Molcure - Contacts, Employees, Board Members, Advisors & Alumni
Molcure is a high-speed, high-quality, high-variation antibody screening & design system combining biology, automation and bioinformaticsSee details»
新経営体制のお知らせ, April 8 | MOLCURE
Apr 8, 2024 · MOLCUREは、世界で最も優れたバイオ医薬品設計プラットフォームを構築することを目指して、2013年に設立されました。 MOLCUREのAI創薬プラットフォーム技術は、 …See details»
The HealthTech Club - Molcure - Japan Based AI Company …
Molcure offers an antibody screening and design platform for drug and treatment development, powered by bioinformatics and automation to support research.See details»
Ryu Ogawa - CEO & Satoshi Tamaki - CSO, Molcure, Japan
Aug 17, 2020 · Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency of the drug …See details»
Molcure - Funding, Financials, Valuation & Investors - Crunchbase
Molcure is a high-speed, high-quality, high-variation antibody screening & design system combining biology, automation and bioinformaticsSee details»
Ono Enters into a Drug Discovery Collaboration Agreement with …
Mar 23, 2023 · Under the terms of the agreement, MOCLURE will discover and identify antibodies or molecules for multiple targets of interest selected by Ono, using MOLCURE’s proprietary AI …See details»
Molcure | VentureRadar
MOLCURE is a growing startup company with a unique biopharmaceutical molecular design technology that makes full use of Artificial Intelligence (AI).... ... Find out more about Molcure, …See details»
Antibody developer Yumab partners with Japanese AI specialist …
Oct 16, 2024 · German antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company's zero-shot AI technology for …See details»
MOLCURE Raises $7.2 million through third-party allocation of …
KAWASAKI, JAPAN – Aug 18, 2021– MOLCURE, an AI-driven drug discovery and developing company, has raised $ 7.2 million in Series C funding. The round was led by Jafco Group and …See details»
Series C - Molcure - 2021-08-18 - Crunchbase Funding Round Profile
Aug 18, 2021 · Molcure raised $7282857 on 2021-08-18 in Series C. Start Free Trial . Chrome ExtensionSee details»
AIを活用した新薬開発を行うMOLCURE、総額8億円の資金調達を …
Aug 18, 2021 · MOLCURE（モルキュア）が提供するバイオ医薬品分子設計技術は、AIとロボットを活用して自動的に大規模スクリーニングと分子設計を行うことが可能であり、既存の …See details»